Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Alzheimers Dis ; 61(3): 843-866, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29332042

RESUMEN

The purpose of our article is to assess the current understanding of Indian spice, curcumin, against amyloid-ß (Aß)-induced toxicity in Alzheimer's disease (AD) pathogenesis. Natural products, such as ginger, curcumin, and gingko biloba have been used as diets and dietary supplements to treat human diseases, including cancer, cardiovascular, respiratory, infectious, diabetes, obesity, metabolic syndromes, and neurological disorders. Products derived from plants are known to have protective effects, including anti-inflammatory, antioxidant, anti-arthritis, pro-healing, and boosting memory cognitive functions. In the last decade, several groups have designed and synthesized curcumin and its derivatives and extensively tested using cell and mouse models of AD. Recent research on Aß and curcumin has revealed that curcumin prevents Aß aggregation and crosses the blood-brain barrier, reach brain cells, and protect neurons from various toxic insults of aging and Aß in humans. Recent research has also reported that curcumin ameliorates cognitive decline and improves synaptic functions in mouse models of AD. Further, recent groups have initiated studies on elderly individuals and patients with AD and the outcome of these studies is currently being assessed. This article highlights the beneficial effects of curcumin on AD. This article also critically assesses the current limitations of curcumin's bioavailability and urgent need for new formulations to increase its brain levels to treat patients with AD.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Barrera Hematoencefálica/efectos de los fármacos , Curcumina/farmacología , Fármacos Neuroprotectores/farmacología , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/toxicidad , Animales , Barrera Hematoencefálica/metabolismo , Modelos Animales de Enfermedad , Humanos , Ratones , Ensayos Clínicos Controlados Aleatorios como Asunto , Especias
2.
Asian Pac J Cancer Prev ; 17(12): 5287-5294, 2016 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-28125875

RESUMEN

Background: Breast cancer is a worldwide public health concern and is the most prevalent type of cancer in women in the United States. This study concerned the best fit of statistical probability models on the basis of survival times for nine state cancer registries: California, Connecticut, Georgia, Hawaii, Iowa, Michigan, New Mexico, Utah, and Washington. Materials and Methods: A probability random sampling method was applied to select and extract records of 2,000 breast cancer patients from the Surveillance Epidemiology and End Results (SEER) database for each of the nine state cancer registries used in this study. EasyFit software was utilized to identify the best probability models by using goodness of fit tests, and to estimate parameters for various statistical probability distributions that fit survival data. Results: Statistical analysis for the summary of statistics is reported for each of the states for the years 1973 to 2012. Kolmogorov-Smirnov, Anderson-Darling, and Chi-squared goodness of fit test values were used for survival data, the highest values of goodness of fit statistics being considered indicative of the best fit survival model for each state. Conclusions: It was found that California, Connecticut, Georgia, Iowa, New Mexico, and Washington followed the Burr probability distribution, while the Dagum probability distribution gave the best fit for Michigan and Utah, and Hawaii followed the Gamma probability distribution. These findings highlight differences between states through selected sociodemographic variables and also demonstrate probability modeling differences in breast cancer survival times. The results of this study can be used to guide healthcare providers and researchers for further investigations into social and environmental factors in order to reduce the occurrence of and mortality due to breast cancer.

3.
J Alzheimers Dis ; 48(2): 547-55, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26402018

RESUMEN

The Garrison Institute on Aging (GIA) is an established institute within Texas Tech University Health Sciences Center, whose mission is to promote healthy aging through cutting-edge research on Alzheimer's disease (AD) and other diseases of aging through innovative educational opportunities for students, clinicians, researchers, health care professionals, and the public. The GIA has multiple programs, including both research and education on healthy aging and AD, community outreach, caregiving, the Retired Senior Volunteer Program, Healthy Lubbock, the GIA Brain Bank, healthy aging seminars, research seminars, and collaborations and scholarships. The GIA programs connect basic and clinical researchers and health care professionals, and provide a unique environment to help our growing elderly population and patients with AD and their families.


Asunto(s)
Centros Médicos Académicos , Enfermedad de Alzheimer/terapia , Servicios de Salud para Ancianos , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/metabolismo , Animales , Encéfalo , Relaciones Comunidad-Institución , Geriatría/educación , Geriatría/métodos , Humanos , Esclerosis Múltiple/metabolismo , Esclerosis Múltiple/terapia , Educación del Paciente como Asunto , Texas , Bancos de Tejidos , Voluntarios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...